AVIR RSI Chart
Last 7 days
0.5%
Last 30 days
5.3%
Last 90 days
-1.5%
Trailing 12 Months
14.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 21.6M | 0 | 0 | 0 |
2023 | 153.5M | 87.5M | 0 | 0 |
2022 | 285.4M | 219.4M | 0 | 0 |
2021 | 124.3M | 200.0M | 275.7M | 351.4M |
2020 | 0 | 0 | 0 | 48.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 01, 2024 | hammond janet mj | sold | -53,913 | 3.843 | -14,029 | chief development officer |
Feb 01, 2024 | vavricka john | sold | -45,420 | 3.843 | -11,819 | chief commercial officer |
Feb 01, 2024 | horga maria arantxa | sold | -60,963 | 3.8414 | -15,870 | chief medical officer |
Feb 01, 2024 | foster wayne | sold | -47,904 | 3.8394 | -12,477 | evp, chief accounting officer |
Feb 01, 2024 | corcoran andrea | sold | -60,914 | 3.8449 | -15,843 | see remarks |
Feb 01, 2024 | sommadossi jean-pierre | sold | -218,819 | 3.845 | -56,910 | president, ceo, and chairman |
Jan 31, 2024 | hammond janet mj | acquired | - | - | 46,800 | chief development officer |
Jan 31, 2024 | vavricka john | acquired | - | - | 33,334 | chief commercial officer |
Jan 31, 2024 | horga maria arantxa | acquired | - | - | 41,534 | chief medical officer |
Jan 31, 2024 | foster wayne | acquired | - | - | 33,334 | evp, chief accounting officer |
Which funds bought or sold AVIR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | reduced | -24.92 | -25,000 | 4,539,000 | 0.01% |
May 13, 2024 | Ameritas Investment Partners, Inc. | unchanged | - | 7,439 | 30,357 | -% |
May 13, 2024 | Frazier Financial Advisors, LLC | unchanged | - | 119 | 485 | -% |
May 13, 2024 | FMR LLC | added | 8.01 | 7,027,770 | 23,347,300 | -% |
May 13, 2024 | STRS OHIO | reduced | -5.96 | 75,000 | 382,000 | -% |
May 13, 2024 | UBS Group AG | reduced | -3.32 | 92,122 | 420,442 | -% |
May 13, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.85 | 36,410 | 152,627 | -% |
May 13, 2024 | SUMMIT SECURITIES GROUP LLC | new | - | 14,000 | 14,000 | -% |
May 13, 2024 | Nuveen Asset Management, LLC | unchanged | - | 288,181 | 1,176,010 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | added | 4.12 | 2,091,330 | 7,606,010 | -% |
Unveiling Atea Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Atea Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 49.2B | 6.8B | -8.24 | 7.18 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.7B | 2.0B | -56.37 | 9.34 | ||||
BMRN | 15.1B | 2.5B | 73.61 | 6.12 | ||||
INCY | 12.8B | 3.8B | 17.19 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.4B | 107.9M | -9.93 | 48.09 | ||||
APLS | 5.0B | 524.1M | -11.99 | 9.55 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 2.8B | 240.7M | -6.04 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.9B | 996.6M | -4.75 | 1.9 | ||||
CRBP | 456.3M | 881.7K | -13.52 | 481.06 | ||||
INO | 297.2M | 4.9M | -2.38 | 61.07 | ||||
IBIO | 16.2M | 2.1M | -0.7 | 7.61 |
Atea Pharmaceuticals Inc News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q2 | 2023Q1 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | -6.0% | 7.00 | 7.00 | 6.00 | 1.00 | 97.00 | 192 | 33.00 | 60.00 | 66.00 | - |
Operating Expenses | 98.1% | 70.00 | 35.00 | 42.00 | 32.00 | 42.00 | 71.00 | 55.00 | 52.00 | 35.00 | 28.00 |
S&GA Expenses | -100.0% | - | 13.00 | 13.00 | 12.00 | 13.00 | 13.00 | 12.00 | 12.00 | 9.00 | 14.00 |
R&D Expenses | 161.0% | 58.00 | 22.00 | 29.00 | 20.00 | 30.00 | 58.00 | 43.00 | 40.00 | 27.00 | 14.00 |
EBITDA Margin | -504.3% | -7.53* | -1.25* | -0.73* | 0.12* | 0.23* | 0.39* | 0.14* | 0.21* | - | - |
Income Taxes | -8.0% | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 6.00 | 7.00 | - | - |
Earnings Before Taxes | -125.3% | -62.94 | -27.93 | -35.27 | -31.21 | -42.08 | 121 | -22.09 | 9.00 | 31.00 | 21.00 |
EBT Margin | -503.5% | -7.55* | -1.25* | -0.73* | 0.12* | 0.23* | 0.39* | 0.14* | 0.21* | - | - |
Net Income | -124.1% | -63.17 | -28.18 | -35.47 | -31.33 | -42.08 | 117 | -28.19 | 2.00 | 31.00 | 21.00 |
Net Income Margin | -526.1% | -7.59* | -1.21* | -0.71* | 0.07* | 0.17* | 0.34* | 0.09* | 0.18* | - | - |
Free Cashflow | -147.3% | -39.86 | -16.12 | -29.85 | -21.06 | -59.05 | -75.43 | 23.00 | -17.35 | - | - |
Balance Sheet | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Assets | -7.0% | 553 | 595 | 608 | 626 | 638 | 667 | 687 | 694 | 717 | 773 | 844 | 872 | 841 | 864 | 110 | - |
Current Assets | -7.1% | 549 | 590 | 603 | 621 | 632 | 661 | 682 | 689 | 713 | 772 | 843 | 871 | 840 | 863 | 108 | 22.00 |
Cash Equivalents | 11.9% | 161 | 144 | 138 | 214 | 183 | 188 | 176 | 684 | 706 | 765 | 840 | 816 | 834 | 850 | 105 | 22.00 |
Net PPE | -8.1% | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 22.3% | 49.00 | 40.00 | 26.00 | 24.00 | 20.00 | 26.00 | 23.00 | 34.00 | 37.00 | 63.00 | 262 | 274 | 254 | 316 | - | - |
Current Liabilities | 27.6% | 41.00 | 32.00 | 19.00 | 16.00 | 12.00 | 18.00 | 16.00 | 25.00 | 29.00 | 57.00 | 262 | 274 | 254 | 316 | 11.00 | 2.00 |
Shareholder's Equity | -9.2% | 504 | 555 | 582 | 602 | 618 | 641 | 663 | 660 | 680 | 710 | 581 | 598 | 586 | 548 | - | - |
Retained Earnings | -32.3% | -259 | -195 | -156 | -123 | -95.35 | -59.88 | -25.45 | -17.38 | 14.00 | 56.00 | -61.10 | -32.91 | -34.45 | -65.16 | -85.82 | -54.21 |
Additional Paid-In Capital | 1.7% | 763 | 751 | 739 | 726 | 714 | 701 | 689 | 678 | 666 | 654 | 642 | 631 | 621 | 613 | 9.00 | 5.00 |
Shares Outstanding | 0.9% | 84.00 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | - | - | - | - |
Float | - | - | - | - | 284 | - | - | - | 537 | - | - | - | 1,615,148 | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Cashflow From Operations | -82.6% | -39,865 | -21,834 | -17,591 | -16,120 | -29,850 | -21,545 | -21,242 | -19,186 | -59,009 | -75,423 | 22,603 | -17,348 | -16,837 | 318,521 | -9,481 | -7,798 | -4,508 | - | - | - |
Share Based Compensation | 3.5% | 12,586 | 12,157 | 12,383 | 12,353 | 12,535 | 11,645 | 11,504 | 11,908 | 11,661 | 11,351 | 10,990 | 10,007 | 7,273 | 2,821 | 4,238 | 209 | 189 | - | - | - |
Cashflow From Investing | 104.5% | 56,802 | 27,771 | -58,513 | 46,565 | 24,480 | 33,488 | -486,975 | -1,879 | -44.00 | - | - | - | - | -5.00 | -15.00 | - | - | - | - | - |
Cashflow From Financing | - | 150 | - | 92.00 | - | 165 | - | 147 | - | 223 | 142 | 795 | 57.00 | 471 | 426,218 | -913 | 106,449 | -6.00 | - | - | - |
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 114,243 | $ 81,936 |
General and administrative | 49,919 | 48,714 |
Total operating expenses | 164,162 | 130,650 |
Loss from operations | (164,162) | (130,650) |
Interest income and other, net | 29,224 | 11,151 |
Loss before income taxes | (134,938) | (119,499) |
Income tax benefit (expense) | (1,018) | 3,590 |
Net loss | (135,956) | (115,909) |
Other comprehensive loss: | ||
Unrealized gain (loss) on available-for-sale investments | 891 | (684) |
Comprehensive loss | $ (135,065) | $ (116,593) |
Net loss per share attributable to common stockholders | ||
Basic | $ (1.63) | $ (1.39) |
Diluted | $ (1.63) | $ (1.39) |
Weighted-average number of common shares - basic and diluted | ||
Basic | 83,389,750 | 83,245,385 |
Diluted | 83,389,750 | 83,245,385 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 143,823 | $ 188,460 |
Marketable securities | 434,283 | 458,249 |
Prepaid expenses and other current assets | 12,349 | 14,213 |
Total current assets | 590,455 | 660,922 |
Property and equipment, net | 1,289 | 1,705 |
Restricted cash | 198 | |
Other assets | 1,396 | 1,494 |
Operating lease right-of-use assets, net | 1,828 | 2,389 |
Total assets | 594,968 | 666,708 |
Current liabilities | ||
Accounts payable | 4,252 | 2,551 |
Accrued expenses and other current liabilities | 27,364 | 15,206 |
Current portion of operating lease liabilities | 760 | 721 |
Total current liabilities | 32,376 | 18,478 |
Operating lease liabilities | 1,642 | 2,403 |
Income taxes payable | 5,758 | 5,255 |
Total liabilities | 39,776 | 26,136 |
Commitments and contingencies (see Note 8) | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022 | ||
Common stock, $0.001 par value; 300,000,000 shares authorized; 83,435,513 and 83,287,639 shares issued and outstanding as of December 31, 2023 and 2022 | 83 | 83 |
Additional paid-in capital | 750,737 | 701,052 |
Accumulated other comprehensive gain (loss) | 207 | (684) |
Accumulated deficit | (195,835) | (59,879) |
Total stockholders’ equity | 555,192 | 640,572 |
Total liabilities and stockholders’ equity | $ 594,968 | $ 666,708 |